CRISPR Therapeutics AG (CRSP) Stock

CRISPR Therapeutics AG (CRSP) is a Healthcare stock trading at $54.06 (as of 2026-06-18), with a market capitalization of $5.42B and a trailing P/E of -8.1. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

CRISPR Therapeutics AG develops gene-based medicines using its CRISPR/Cas9 gene-editing platform, advancing therapeutic programs across disease areas such as hemoglobinopathies and oncology. Its pipeline includes ex vivo and donor-derived gene-edited cell therapies, including CTX001 and investigational CAR-T programs (CTX110, CTX120, and CTX130) targeting specific malignancies.

Valuation — source: SEC EDGAR (first-party)
Price$54.06
Market Cap$5.42B
P/E Ratio-8.1
EV / EBITDA-7.9
Price / Book2.65
Price / Sales1170.64
DCF Value (model)$-57.73
DCF Upside vs Price-206.8%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$3.51M
Net Margin-16569.8%
Return on Equity-31.3%
Debt / Equity0.32
Current Ratio17.96
Revenue Growth (YoY)-90.6%
EPS Growth (YoY)49.1%
FCF Growth (YoY)139.1%
Financial Health — source: SEC EDGAR
Altman Z-Score7.87 (safe)
Valuation vs Sector & Industry
Stock P/E-8.1
Sector P/E (Healthcare)21.0
Industry P/E (Pharmaceutical Products)17.3
vs Sector-138.5%
vs Industry-146.8%
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderARK Investment Management LLC ($538.19M)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryPharmaceutical Products
CEOSamarth Kulkarni
Employees393
CountryCH
IPO Date2016-10-19

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

  • Protagonist Therapeutics, Inc. (PTGX)
  • Apogee Therapeutics, Inc. (APGE)
  • Immunovant, Inc. (IMVT)
  • Scholar Rock Holding Corporation (SRRK)
  • Arrowhead Pharmaceuticals, Inc. (ARWR)
  • Alkermes plc (ALKS)
  • Indivior Pharmaceuticals Inc (INDV)
  • ACADIA Pharmaceuticals Inc. (ACAD)
CRSP earnings history · CRSP institutional & insider holders · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.